

## Conference Program ASAM 56th Annual Conference

April 24-27, 2025 | Denver, CO



More information in the app!

**Pre-Conference Courses** 

Thursday, April 24, 2025 | 9:00 am - 4:30 pm

Separate Registration Required

PAIN & ADDICTION:

STIMULANT USE DISORDER

### **Conference Organizers**

#### **Annual Conference Program Planning Committee**

Anika A. H. Alvanzo, MD. MS. FACP, DFASAM (Chair) Nassima Ait-daoud Tiouririne, MD, FASAM

Saad Alvi, MD

Barbara Andraka-Christou, JD, PhD

Fiona Axelsson, MD

Subhadeep Barman, MD, FAPA, FASCP, FASAM

Ricky Bluthenthal, PhD

Julie W. Childers, MD, FASAM

Nicholaus Christian, MD, MBA, FASAM

Jeremiah Fairbanks, DO, FASAM

Oluwaseun Falade-Nwulia, MBBS, MPH

Michael Fingerhood, MD, FACP, DFASAM

Sabrina Gill, MD

Jessica Howard, CNM, MSN, MSW

Amy Kennedy, MD, MS, FASAM

Jason D. Kirby, DO, MBA, DFASAM

Ian Latham, MD

Kylie Morris, DO

Lewis S. Nelson, MD, MBA, DFASAM

Awawu Ojikutu, CRNP

Jeanmarie Perrone, MD, FASAM

Jarratt Pytell, MD, MHS

Lee Radosh, MD, FAAFP, FASAM

Amutha Rajagopal, MD, MPH, FASAM

Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM

Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM,

DFASAM

Evan Schwarz, MD, FACEP, FACMT, FASAM

Robert C. Sherrick, MD. DFASAM

Kento Sonoda, MD, AAHIVS, FASAM

Bernard Stuetz, Jr., PA-C, MA

Steven Tate, MD, MSc, FASAM

J. Deanna Wilson, MD, MPH, FASAM

#### Jared Harp, DO

Hiroko Furo, MD, PhD, MA, MS, MSES, FASAM

**Annual Conference Abstract Reviewers** 

Keri Holmes Maybank, MD, MSCR

Tom Hutch, MD, FASAM

Daniel Liauw, MD, MPH

Mary Lonergan-Cullum, PhD

Emily Loscalzo, PsyD, MAC, NCSE

Sheryl Lyss, MD, MPH, FASAM

Nathan Menke, MD, PhD, FASAM

Alex Rahimi, MD

Charles Schauberger, MD, DFASAM

Lorien Shack, MD, MPH

Jessica Wang, MD, MPH

Jeny Williams-Rodrigue, LMHP, SAP

#### **ASAM CE Committee & Reviewers**

Pamela J. Shultz, MD, DFASAM (Chair)

Jennifer Aldea, PA-C

Catharina Armstrong, MD, FASAM

Subhadeep Barman, MD, FAPA, FASCP, FASAM

Benjamin Bearnot, MD, MPH, FASAM

Arielle Bivas, CRNP, AGPCNP-BC

Arianna Campbell, MPH, PA-C

Laura Frankart, PharmD, MEd, BCPS

Eman Gibson, LCSW, LCADC

Herbert L. Malinoff, MD, FACP, DFASAM

Kayla Nelson, DNP, FNP-C, CARN-AP

Kathryn Nevins, DNP, NP-C, APRN

John D. Perra, LCSW

Cara A. Poland, MD, MEd, FACP, DFASAM

Edwin A. Salsitz, MD, DFASAM

Mark Weiner, MD, DFASAM

#### Agency Representatives

Yngvild Olsen, MD, MPH, DFASAM (SAMHSA Liaison) Deidra Roach, MD (NIAAA Liaison) Geetha Subramaniam, MD (NIDA Liaison)







### **Session Types:**

**CS** = Collaborative Session **GS** = General Session

FS = Focus Session

**WS** = Workshop Session

The full conference schedule, including speaker information, presentation slides, and more is available on the conference website (https://annualconference.asam.org/) and in the ASAM Events app.

### **Pre-Conference Activities**

Wednesday, April 2	3	
5:00 pm - 8:00 pm	ASAM Registration Open	Valley Foyer, Level 2
9:00 pm - 10:00 pm	Mutual Help (Open Meeting)	Crest 2, Level 2
Thursday, April 24		
7:00 am - 8:00 am	Mutual Help (Open Meeting)	Crest 2, Level 2
7:30 am - 7:00 pm	ASAM Registration Open	Valley Foyer, Level 2
8:00 am - 9:00 am	<b>Pre-Conference Course Continental Breakfast</b> Included with Pre-Conference Course Registration Fee	Multiple Locations
9:00 am - 4:30 pm	ASAM Stimulant Use Disorder Course - (6.00 CE) Separate Registration Required	Aurora Ballroom A, Level 2
	Pain & Addiction: Common Threads Course XXVI – (6.00 CE) Separate Registration Required	Aurora Ballroom D, Level 2
3:00 pm - 7:00 pm	ASAM Booth Open	Rockies Square, Level 2

### **Annual Conference Begins**

	2.1.2.2.2.30.1.12	
5:00 pm - 7:00 pm	Exhibit Hall Open	Aurora Hall 1 & 2, Level 2
	Wilderness Welcome Reception	Aurora Hall 1 & 2, Level 2
6:00 pm - 6:30 pm	Child & Adolescent Addiction Special Interest Group Meet-Up	Lounge 1, Aurora Hall 1 & 2, Level 2
	First-Time Attendee Meet-Up	Lounge 2, Aurora Hall 1 & 2, Level 2
	Women & Substance Use Disorders Special Interest Group Meet-Up	Lounge 3, Aurora Hall 1 & 2, Level 2
6:00 pm - 7:00 pm	Region IV Meeting (NJ, OH, PA)	Red Rock 4-5, Level 3
	Region IX Meeting (Canada/International)	Red Rock 2-3, Level 3
	Region VI Meeting (IA, IL, IN, MI, MN, WI)	Homestead 3-4, Level 3
6:30 pm - 8:00 pm	President's Donor Reception (Invitation Only)	Colorado Pre-Function, Level 3
7:00 pm - 8:00 pm	Becoming Certified in Addiction Medicine and How to Continue That Certification – (1.00 CE) Developed in Collaboration with the American Board of Preventive Medicine Michael F. Weaver, MD, DFASAM; Christopher J. Ondrula, JD	Aurora Ballroom D, Level 2 CS
	Developing Addiction Medicine Fellowships – (1.00 CE) Developed in Collaboration with the American College of Academic Addiction Medicine Timothy K. Brennan, MD, MPH; Jeanette M. Tetrault, MD, FACP, FASAM; Alexander Y. Walley, MD, MSc, DFASAM	Aurora Ballroom A, Level 2 CS
7:30 pm - 8:30 pm	New Member Dessert Reception (Invitation Only)	Willow Lake 3-5, Level 3
9:00 pm - 10:00 pm	Mutual Help (Open Meeting)	Crest 2, Level 2

Friday, April 25			
7:00 am - 8:00 am	Morning Yoga Class	Colorado Foyer, Level 3	
	Mutual Help (Open Meeting)	Crest 2, Level 2	
	Scholarship Networking Breakfast Meeting	Homestead 3-4, Level 3	
7:30 am - 8:30 am	Continental Breakfast	Aurora Hall 1 & 2, Level 2	
7:30 am - 3:00 pm	Exhibit Hall Open	Aurora Hall 1 & 2, Level 2	
7:30 am - 4:00 pm	ASAM Registration Open	Valley Foyer, Level 2	
7:30 am - 5:45 pm	ASAM Booth Open	Rockies Square, Level 2	
8:00 am - 8:30 am	NP/PA Meet-Up	Lounge 1, Aurora Hall 1 & 2, L	evel 2
	Opioid Treatment Program Special Interest Group Meet-Up	Lounge 2, Aurora Hall 1 & 2, L	evel 2
	Primary Care & Family Medicine Special Interest Group Meet-Up	Lounge 3, Aurora Hall 1 & 2, L	evel 2
8:30 am - 9:45 am	Opening General Session - Transforming Care through Innovative Community-Based Models - (1.25 CE) Caleb Banta-Green, PhD, MPH, MSW; Avik Chatterjee, MD, MPH; Everett Maroon, MPH; Sarah Messmer, MD, FASAM	Colorado Ballroom, Level 3	GS
9:45 am - 10:30 am	Break	Aurora Hall 1 & 2, Level 2	
	Scientific Poster Session 1a - (0.75 CE)	Aurora Pre-Function, Level 2	
10:00 am - 10:30 am	Behavioral Addiction Special Interest Group Meet-Up	Lounge 1, Aurora Hall 1 & 2, L	evel 2
	LGBTQ+ Special Interest Group Meet-Up	Lounge 2, Aurora Hall 1 & 2, L	evel 2
	Meet the JAM Editors	Lounge 3, Aurora Hall 1 & 2, L	evel 2
10:30 am - 11:45 am	Annual Review of Addiction Medicine: Highest Impact Publications from 2024-2025 – (1.25 CE) Sarah E. Wakeman, MD, FASAM; Joshua D. Lee, MD, MSc	Colorado Ballroom, Level 3	FS
	Complexities and Controversies in Assessing, Diagnosing, and Managing Kratom Use – (1.25 CE) Kirsten E. Smith, MSW, PhD; Stephanie T. Weiss, MD, PhD, FAACT, FASAM; Ian Latham, MD; Robert B. Levy, MD, FASAM	Aurora Ballroom A, Level 2	FS
	Developing and Evaluating the ASAM Criteria Level of Care Assessment Guide – (1.25 CE) Itai Danovitch, MD, MBA, DFAPA, DFASAM; John Smith, PhD, LCSW; Gregory Hobelmann, MD, MPH; Anne B. Lee, MSW, LCSW; Eman Gibson, LCSW, LCADC	Willow Lake 3-5, Level 3	FS
	Guidelines for Managing Stimulant Use Disorder: Applying a Pregnancy and Postpartum Lens – (1.25 CE) Niraj R. Chavan, MD, MPH, FACOG, FASAM; Cresta W. Jones, MD, FACOG, FASAM; Maria Manriquez, MD, FACOG, PMH-C, FASAM	Aurora Ballroom C, Level 2	FS
	Harm Reduction is Healthcare: Decreasing Risk and Stigma With People Who Use Drugs – (1.25 CE) Ruchi V. Shah, DO; Emily Regier, MD; Stephen P. Murray, MPH, NRP; Theresa Rolley, MA; Betsy Craft, CPFS; Karri Weisenthal, MD, MHS; Alexander Y. Walley, MD, MSc, DFASAM	Aurora Ballroom B, Level 2	WS
	Implementing SAMHSA's Final Rule: Challenges and Outcomes for Opioid Treatment Programs – (1.25 CE) Robert C. Sherrick, MD, DFASAM; Hillary Tamar, MD, FASAM; Mark Schaefer, EdS, MA	Aurora Ballroom D, Level 2	FS

Friday, April 25			
10:30 am - 11:45 am	Improving Outcomes for Youth OUD Treatment – (1.25 CE) Marc Fishman, MD, DFASAM; Sivabalaji Kaliamurthy, MD, FASAM; Kevin R. Wenzel, PhD	Red Rock 8-9, Level 3	FS
	It's Jail, Doc, We Don't Do Buprenorphine: MOUD Advocacy in Indiana's Jails – (1.25 CE) Krista M. Brucker, MD; Amelia Caramadre, Esq, MPH; Brooke Marshall, LCSW, LCAC	Red Rock 6-7, Level 3	FS
	Using Data to Inform and Improve Recovery Equity – (1.25 CE) Anika Alvanzo, MD, MS, FACP, DFASAM; Zina Rodriguez, MSW, MCAP, CDE; Kamala Greene Genece, PhD; Annie Peters, PhD, LP	Crest 3-5, Level 2	WS
11:45 am - 1:15 pm	Lunch Break	Aurora Hall 1 & 2, Level 2	
12:15 pm - 1:15 pm	Region II Meeting (CA)	Homestead 3-4, Level 3	
	Region III Meeting (CT, MA, ME, NH, RI, VT)	Red Rock 4-5, Level 3	
	Region V Meeting (DE, DC, GA, MD, NC, SC, VA, WV)	Red Rock 2-3, Level 3	
	Scientific Poster Session 1b - (1.00 CE)	Aurora Pre-Function, Level 2	
12:30 pm - 1:00 pm	Harm Reduction Special Interest Group Meet-Up	Lounge 1, Aurora Hall 1 & 2, L	evel 2
	Psychedelic Medicine Special Interest Group Meet-Up	Lounge 2, Aurora Hall 1 & 2, L	evel 2
	Twelve-Step Recovery Special Interest Group Meet-Up	Lounge 3, Aurora Hall 1 & 2, L	evel 2
1:15 pm - 2:30 pm	Addiction Medicine and the Law: How to Become an Expert Witness – (1.25 CE) Michael F. Weaver, MD, DFASAM; Kelly J. Clark, MD, MBA, DLFAPA, DFASAM; Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM	Crest 3-5, Level 2	FS
	Healing Practice: Integrating Cultural Awareness into Evidence-Based Addiction Treatment – (1.25 CE) Charles Reznikoff, MD, FACP, FASAM; Ese B. Aghenta, MD, MPH, FAAFP, FASAM; Cailean Dakota MacColl; Seleipiri I. Akobo, MD, MBA, MPH, DABOM, FASAM; Omar Hassan, MD	Aurora Ballroom D, Level 2	WS
	How Low Can You Go? Low-Barrier Buprenorphine Care Delivery Models – (1.25 CE) Elizabeth M. Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM; Sarah Messmer, MD, FASAM; Katrina Ciraldo, MD; Edward Suarez, Jr., PsyD, LMHC	Colorado Ballroom, Level 3	FS
	Injectable Medications for Addiction: Hands-On Practice for Providers – (1.25 CE) Room Capacity Limited to 150 Megan Ehret, PharmD, MS, BCPP, FAAPP; Jaden Dickinson, PharmD, BCPP; Hannah Wilkoff, PharmD, BCPP; Vincent S. Cavaliere, PharmD, MM, BCPP; Mark Bickley, PharmD, BCPP; Jaden Todd	Aurora Ballroom B, Level 2	WS
	Methadone Initiation for Opioid Use Disorder in the Emergency Department – (1.25 CE) Rachel Haroz, MD; Joseph D'Orazio, MD, FAAEM, FACMT, FCPP, FASAM; Matthew Salzman, MD, MPH; Bill E. Soares, III, MD, MS; Ryan P. McCormack, MD, MS	Aurora Ballroom C, Level 2	FS

Friday, April 25			
1:15 pm - 2:30 pm	Navigating Substance Use Coercion: Practical Tools for Screening and Intervention – (1.25 CE) Diana Samberg, MD, MS; Ilana Hull, MD, FASAM; Carole Warshaw, MD	Willow Lake 3-5, Level 3	WS
	Outpatient Alcohol Withdrawal Treatment: Best Evidence and Updates from Literature – (1.25 CE) Zachary Sartor, MD, FAAFP; Ryan Laschober, MD, FAAFP; Natalie Fjellanger, LCSW	Red Rock 8-9, Level 3	FS
	Safe Tapering of Benzodiazepines: Insights from Joint Clinical Practice Guideline – (1.25 CE) Emily Brunner, MD, DFASAM; Chinyere Ogbonna, MD, MPH; Tricia E. Wright, MD, MS, FACOG, DFASAM	Aurora Ballroom A, Level 2	WS
2:30 pm - 3:00 pm	Break	Aurora Hall 1 & 2, Level 2	
	Addiction Consult Special Interest Group Meet-Up	Lounge 1, Aurora Hall 1 & 2, I	_evel 2
	Criminal Justice Special Interest Group Meet-Up	Lounge 2, Aurora Hall 1 & 2, I	_evel 2
	Pain & Palliative Care Special Interest Group Meet-Up	Lounge 3, Aurora Hall 1 & 2, I	_evel 2
3:00 pm - 4:15 pm	Cannabinoids and Pregnancy: ASAM Members, Patients, and the Public - A Vital Discourse/Debate - (1.25 CE) Gregory C. Bunt, MD, DFISAM, FASAM; Stephen M. Taylor, MD, MPH, DFAPA, FISAM; Katrina Mark, MD, FACOG, FASAM; Sheryl A. Ryan, MD, FAAP, FASAM	Colorado Ballroom, Level 3	FS
	Centralizing MOUD Access: Removing Barriers through a Statewide Telemedicine Hotline – (1.25 CE) Maria Bruni, PhD; Miao J. Hua, MD, PhD, MPH; Nicole M. Gastala, MD	Red Rock 8-9, Level 3	FS
	Hepatitis C Treatment: Meeting Our Patients Wherever They Are – (1.25 CE) Sarah Rowan, MD; Kevin Kamis, MPH; Ruth Kanatser; Hannan M. Braun, MD	Red Rock 6-7, Level 3	FS
	Injectable Medications for Addiction: Hands-On Practice for Providers – (1.25 CE) Room Capacity Limited to 150 Megan Ehret, PharmD, MS, BCPP, FAAPP; Jaden Dickinson, PharmD, BCPP; Hannah Wilkoff, PharmD, BCPP; Vincent S. Cavaliere, PharmD, MM, BCPP; Mark Bickley, PharmD, BCPP; Jaden Todd	Aurora Ballroom B, Level 2	WS
	Maximizing AA Referrals: Understanding the History and Power of Self-Help Meetings - (1.25 CE) Sherry Nykiel, MD, FASAM; Vaibhav Vyas, MD; Stanley Nkemjika, MD, MPH	Crest 3-5, Level 2	WS
	Monitoring the Wild West of Psychedelic Proliferation - (1.25 CE)  Dale J. Terasaki, MD, MPH; Andrew A. Monte, MD, PhD	Aurora Ballroom C, Level 2	FS
	NIH HEAL Initiative: Results from Selected NIDA Clinical Trials Network Studies – (1.25 CE) Developed in Collaboration with the National Institute on Drug Abuse Geetha A. Subramaniam, MD, DLFAPA, DFAACAP; Jennifer McNeely, MD, MS; Adam M. Bisaga, MD; Edward V. Nunes, Jr., MD, FASAM; Kathryn F. Hawk, MD, MHS	Aurora Ballroom D, Level 2	CS

Friday, April 25			
3:00 pm - 4:15 pm	Optimizing Engagement and Retention of Nonabstinent Patients in Care - (1.25 CE) Brian Hurley, MD, MBA, FAPA, DFASAM; Eman Gibson, LCSW, LCADC; Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM	Aurora Ballroom A, Level 2	WS
	Sexualized Drug Use and Chemsex: A Case-Based Workshop - (1.25 CE) Cara Borelli, DO; Chun M. Tong, MD; Newman Kessler, MD; Alyssa Cheng, DO	Willow Lake 3-5, Level 3	WS
4:15 pm - 4:30 pm	Break	Colorado Pre-Function, Level 3	3
4:30 pm - 5:45 pm	General Session - The Science of GLP-1 Receptor Agonists: A Rising Tide in Addiction Treatment - (1.25 CE) Joji Suzuki, MD; Sarah E. Wakeman, MD, FASAM; Stephanie T. Weiss, MD, PhD, FAACT, FASAM; Luba Yammine, PhD, APRN, FNP-C	Colorado Ballroom, Level 3	GS
5:45 pm - 7:30 pm	Rockies Reception	Juniper Ballroom, Level 1	
9:00 pm - 10:00 pm	Mutual Help (Open Meeting)	Crest 2, Level 2	
Saturday, April 26			
7:00 am - 8:00 am	Morning Yoga Class	Colorado Foyer, Level 3	
	Mutual Help (Open Meeting)	Crest 2, Level 2	
7:30 am - 8:30 am	Continental Breakfast	Aurora Hall 1 & 2, Level 2	
7:30 am - 1:30 pm	Exhibit Hall Open	Aurora Hall 1 & 2, Level 2	
7:30 am - 2:00 pm	ASAM Registration Open	Valley Foyer, Level 2	
7:30 am - 5:30 pm	ASAM Booth Open	Rockies Square, Level 2	
8:00 am - 8:30 am	Integrative Behavioral Health for Addiction Special Interest Group Meet-Up	Lounge 1, Aurora Hall 1 & 2, Le	evel 2
	Physicans Health Special Interest Group Meet-Up	Lounge 2, Aurora Hall 1 & 2, Le	vel 2
	Science Initiative Special Interest Group Meet-Up	Lounge 3, Aurora Hall 1 & 2, Le	vel 2
8:30 am - 9:45 am	Policy & Science General Session - Policy to Practice: Advancing State Level Change to Improve Addiction Care - (1.25 CE) Chad D. Elkin, MD, FAACP, DFASAM; Cara A. Poland, MD, MEd, FACP, DFASAM; Stephanie B. Stewart, MD, MPHS, MRO, FASAM; Stephen M. Taylor, MD, MPH, DFAPA, DFASAM	Colorado Ballroom, Level 3	GS
9:45 am - 10:30 am	Break	Aurora Hall 1 & 2, Level 2	
	Scientific Poster Session 2a – (0.75 CE)	Aurora Pre-Function, Level 2	
10:00 am - 10:30 am	International Addiction Medicine Special Interest Group Meet-Up	Lounge 1, Aurora Hall 1 & 2, Le	evel 2
	Medical Toxicology Special Interest Group Meet-Up	Lounge 2, Aurora Hall 1 & 2, Le	vel 2
	Telehealth Special Interest Group Meet-Up	Lounge 3, Aurora Hall 1 & 2, Le	vel 2

Saturday, April 26			
10:30 am - 11:45 am	Anyone Can Treat! Master Youth Cannabis Use Treatment for Your Practice Setting – (1.25 CE) Gerald Busch, MD, MPH, DLFAPA, DFAACAP, FASAM; Ravi Shankar, MD, DFAACAP	Aurora Ballroom D, Level 2	WS
	Assessment and Treatment of Alcohol Withdrawal – (1.25 CE) Developed in Collaboration with the Providers Clinical Support System - Medications for Alcohol Use Disorder Stephen Holt, MD, MS, FACP, FASAM; Tessa Steel, MD, MPH	Aurora Ballroom A, Level 2	CS
	Emerging Neuromodulation Techniques: Treatment of SUDs with TMS and Focused Ultrasound – (1.25 CE) Kira V. Panzer, MD; Jamie Gentry, DO; Joseph A. Legan, MD; Nassima Ait-Daoud, MD, FASAM	Red Rock 8-9, Level 3	FS
	Games, Sex, and Social Media: Current Perspectives – (1.25 CE) Sara J. Polley, MD, FAPA, FASAM; Emily Brunner, MD, DFASAM; Shane W. Kraus, PhD	Colorado Ballroom, Level 3	FS
	Hospitals as the Frontline for Addiction: Lessons from the START Study – (1.25 CE) Itai Danovitch, MD, MBA, DFAPA, DFASAM; Stephen Ryzewicz, MD, FACP, DFASAM; Sergio Huerta, II, MD, FASAM; Allison J. Ober, MSW, PhD; Karen Chan Osilla, PhD	Aurora Ballroom B, Level 2	WS
	Making Take-Home Methadone a Reality – (1.25 CE) Angela Kerins, PharmD, BCPS; JP Murray, MD, MA; A. Justine Landi, MD, MPH; Geoff Pucci, PharmD	Aurora Ballroom C, Level 2	WS
	Meeting People "Where They Are:" Integrating Medical Care into Harm Reduction Space – (1.25 CE) Susan Spratt; Benjamin T. Hayes, MD; Andrea U. Jakubowski, MD, MS; Teresa Lopez-Castro, PhD; Michael Pappas, MD	Crest 3-5, Level 2	FS
	Navigating Breastfeeding in the Context of Substance and Opioid Use Disorders – (1.25 CE) Michelle A. Cabán-Ruiz, PhD; Angélica M. Fuentes-Armesto, MD, DABFM; Henry X. Nieves-Díaz, MD, DABFM	Red Rock 6-7, Level 3	FS
	Treatment of Substance Use Disorders Across the Criminal Justice Continuum – (1.25 CE) Joshua Hammond, MD; Dayna DeHerrera-Smith, MPH; Karissa Gayosso, AGACNP-BC	Willow Lake 3-5, Level 3	WS
11:45 am - 1:15 pm	Lunch Break	Aurora Hall 1 & 2, Level 2	
12:15 pm - 1:15 pm	Region I Meeting (NY)	Red Rock 2-3, Level 3	
	Region VII Meeting (AR, OK, KS, LA, MO, NE, TX)	Red Rock 4-5, Level 3	
	Region VIII Meeting (AK, AZ, CO, HI, ID, MT, NM, ND, NV, OR, SD, UT, WA, WY)	Homestead 3-4, Level 3	
	Scientific Poster Session 2b – (1.00 CE)	Aurora Pre-Function, Level 2	
12:30 pm - 1:00 pm	Cannabis & Pregnancy Special Interest Group Meet-Up	Lounge 1, Aurora Hall 1 & 2, Lev	
	Forensic Addiction Medicine Special Interest Group Meet-Up	Lounge 2, Aurora Hall 1 & 2, Lev	vel 2
	Nicotine & Tobacco Special Interest Group Meet-Up	Lounge 3, Aurora Hall 1 & 2, Lev	vel 2

Saturday, April 26			
1:15 pm - 2:30 pm	An Aging Population: Caring for Older Adults with Substance Use Disorders – (1.25 CE) Jennifer Y. Moyer, MD, MPH	Red Rock 6-7, Level 3	FS
	Contingency Management: Overcoming Implementation Barriers to Bring Science to Practice – (1.25 CE) Sara C. Parent, ND; K. Michelle Peavy, PhD; Michael G. McDonell, PhD	Colorado Ballroom, Level 3	FS
	Creation of a Protocol for Pediatric OUD in the ED – (1.25 CE) Deepa R. Camenga, MD, MHS; Stephen M. Sandelich, MD; Shan Yin, MD, MPH, FAAP, FACMT	Aurora Ballroom D, Level 2	WS
	From Submission to Success: Insider Tips for Getting Your Addiction Content Published – (1.25 CE) David A. Fiellin, MD, FASAM; Chung Jung Mun, PhD; Orrin D. Ware, PhD, MPH, MSW; Alexa Anderson, PhD	Aurora Ballroom B, Level 2	FS
	Improving HIV PrEP Use in Eligible Minorities with Substance Use Disorders – (1.25 CE) Moronkeji Fagbemi, MD, FACP, FASAM; Jean Marie, MD; Zerimar Ramirez Lopez, MD	Aurora Ballroom C, Level 2	WS
	Methadone in the Correctional System: To an OTP and Beyond – (1.25 CE) Jessica R. Krueger, MD; Kasey S. Grohe, DNP, FNP-BC, RN; Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM; Catherine L. Smith, DO, FASAM	Willow Lake 3-5, Level 3	FS
	Perinatal Management of Emerging Substance Use Threats and Implications for Maternal Care – (1.25 CE) Niraj R. Chavan, MD, MPH, FACOG, FASAM; Cresta W. Jones, MD, FACOG, FASAM; Maria Manriquez, MD, FACOG, PMH-C, FASAM	Red Rock 8-9, Level 3	FS
	Redesigning Specialty Substance Use Disorder Systems to Better Reach the 95% – (1.25 CE) Brian Hurley, MD, MBA, FAPA, DFASAM; Baldomero "Junie" Gonzalez, MPA, CADC-III; Vanessa Lam, MPH, MPP	Aurora Ballroom A, Level 2	WS
	The Open-Access Model: An Innovative Way to Lower Opioid Treatment Program Barriers – (1.25 CE) Marina Gaeta Gazzola, MD; Jeanette M. Tetrault, MD, FACP; Declan T. Barry, PhD; Lynn M. Madden, PhD, MPA	Crest 3-5, Level 2	FS
2:30 pm - 2:45 pm	Ice Cream Social	Colorado Pre-Function, Level 3	
2:45 pm - 4:00 pm	ASAM Annual Awards & Updates See more details on page 16 Brian Hurley, MD, MBA, FAPA, DFASAM	Colorado Ballroom, Level 3	
4:00 pm - 4:15 pm	Break	Colorado Pre-Function, Level 3	
4:15 pm - 5:30 pm	Bridging the Gap between Science and Clinical Practice – (1.25 CE) Developed in Collaboration with the National Institute on Drug Abuse Wilson M. Compton, MD, MPE; Geetha A. Subramaniam, MD, DLFAPA, DFAACAP; Kenneth I. Freedman, MD, MS, MBA, FACP, AGAF, DFASAM	Aurora Ballroom B, Level 2	CS

Saturday, April 26			
4:15 pm - 5:30 pm	Emerging Illicit Substances: What Clinicians Need to Know - (1.25 CE) Alaina R. Steck, MD, FASAM; Jeanmarie Perrone, MD, FASAM; Rachel S. Wightman, MD, FACMT, FASAM; Daniel J. Sessions, MD, FASAM	Colorado Ballroom, Level 3	FS
	From Tabs to Jabs: Practical Tips to Provide Long-Acting Injectable Buprenorphine – (1.25 CE) Judy S. Chertok, MD; Rachael Truchil, MD, MPH; Stephen Holt, MD, MS, FACP, FASAM; Irina (Era) V. Kryzhanovskaya, MD	Aurora Ballroom A, Level 2	WS
	I'm Not Okay with This (Am I?): Ethical Challenges in Person-Centered Care – (1.25 CE) Ashley Curry, MD; Tanya Michelle Gershmel, CPFS, CNA, QMAP; Allison Forrest, LCSW, LAC	Aurora Ballroom C, Level 2	WS
	Medical Management of Alcohol Use Disorder in Pregnancy and the Peripartum Period – (1.25 CE) Brent Schnipke, MD; Gayane Archer, MD; Kakra Boye-Doe, MD; Faith Horbatch, MD	Willow Lake 3-5, Level 3	FS
	Revolutionizing Methadone Initiation: A Virtual Approach to Accessible Care – (1.25 CE)  J. Stryder ZoBell, BMsc, MD, MBA, CCFP; Lindsey Davis, MPH	Red Rock 6-7, Level 3	FS
	Shared Decision-Making: A Successful Framework for Starting Buprenorphine – (1.25 CE) Wesley Brewington, CPC, CDC II, NCPRSS; Drew Mossman, FNP, PMHNP; Danielle Bellosi, NCPRSS, CPRC; Elizabeth B. Ryan, MD, FASAM	Red Rock 8-9, Level 3	FS
	Understanding and Supporting LGBTQ+ Individuals in Methamphetamine Recovery – (1.25 CE) Lucy Ogbu-Nwobodo, MD, MS, MAS; Kevin J. Shone, CAADC-II; Pierre-Cedric Crouch, PhD, NP; Harminder K. Gill, MD	Aurora Ballroom D, Level 2	WS
5:30 pm - 6:00 pm	Book Signing with Maia Szalavitz	ASAM Booth, Rockies Square,	Level 2
5:45 pm - 6:30 pm	Reflections: ASAM Advocacy Efforts in Early 2025	Aurora Ballroom D, Level 2	
5:45 pm - 6:45 pm	Region X Meeting (AL, FL, KY, MS, PR, TN, VI)	Homestead 3-4, Level 3	
9:00 pm - 10:00 pm	Mutual Help (Open Meeting)	Crest 2, Level 2	
Sunday, April 27			
7:00 am - 8:00 am	Mutual Help (Open Meeting)	Crest 2, Level 2	
	Scholarship Networking Breakfast Meeting	Homestead 3-4, Level 3	
7:30 am - 8:30 am	Continental Breakfast	Aurora Pre-Function, Level 2	
7:30 am - 10:00 am	ASAM Registration Open	Valley Foyer, Level 2	
7:30 am - 11:30 am	ASAM Booth Open	Rockies Square, Level 2	
8:30 am - 9:45 am	Advocating to Advance Addiction Policy in Your State – (1.25 CE) Stephanie B. Stewart, MD, MPHS, MRO, FASAM; Moxie L. Loeffler, DO, MPH, FASAM; Lucinda A. Grande, MD, FASAM	Aurora Ballroom C, Level 2	WS
	Health System Change to Address Disparities in Opioid Use Disorder Treatment – (1.25 CE) Tiffany Y. Lu, MD, MS, FASAM; Jennifer Mark, MD	Aurora Ballroom D, Level 2	WS

Sunday, April 27			
8:30 am - 9:45 am	Intervening with Women and Girls Who Drink at Harmful Levels – (1.25 CE) Developed in Collaboration with the National Institute on Alcohol Abuse and Alcoholism Carley Castellanos, MA, LMFT; Robert Miranda, Jr., PhD, ABPP; Sara Jo Nixon, PhD; Anika A.H. Alvanzo, MD, MS, FACP, DFASAM	Crest 3-5, Level 2	CS
	Management of Benzodiazepine Withdrawal in the Outpatient and Non-Hospital Settings – (1.25 CE) Robert Cole Pueringer, MD; Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM; JoAn Laes, MD, FACMT, DFASAM; Soumya L. Pandalai, MD, FACP, DFASAM	Aurora Ballroom A, Level 2	FS
	Xylazine-Associated Wounds: Clinical Insights, Challenges, and Management Strategies – (1.25 CE) Joseph D'Orazio, MD, FAAEM, FACMT, FCPP, FASAM; Raagini Jawa, MD, MPH, FASAM; Tehya Johnson, BSN, MSN, AGPCNP-BC; Lisa Rae, MD, FACS	Aurora Ballroom B, Level 2	FS
9:45 am - 10:15 am	Break	Aurora Pre-Function, Level 2	
10:15 am - 11:30 am	Breaking Barriers to Maternal Treatment for OUD: Strategies for Engagement and Retention - (1.25 CE) Jessica L. Young, MD, MPH, FASAM; Kim Lovell, MPH, MBA; Rachel N. King, CPRS; Samuel Hinkes, MD, MPH	Aurora Ballroom C, Level 2	WS
	Current Challenges in Adolescent Addiction Care: Vision for the Future – (1.25 CE) Sandra Gomez-Luna, MD, FAPA, FASAM; Lisa R. Fortuna, MD, MPH; Modar Sukkarieh, MD, FAAP; Sara J. Polley, MD, FAPA, FASAM	Crest 3-5, Level 2	FS
	DEA Overview and Update - (1.25 CE) Developed in Collaboration with the Drug Enforcement Agency Heather E. Achbach; Stephen M. Taylor, MD, MPH, DFAPA, DFASAM	Aurora Ballroom D, Level 2	CS
	Heavy Hitters: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Addiction Treatment – (1.25 CE) Michael F. Weaver, MD, DFASAM; Luba Yammine, PhD, APRN, FNP-C; Nancy C. Shenoi, MD	Aurora Ballroom B, Level 2	FS
	Innovative Buprenorphine Initiation Strategies – (1.25 CE) Melissa B. Weimer, DO, MCR, DFASAM; Andrew A. Herring, MD; Pouya Azar, MD, FRCPC; David Wolinsky, MD	Aurora Ballroom A, Level 2	FS
	End of the ASAM 56th Annual Conference.		



#### **Joint Accreditation Statement**

In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The American Society of Addiction Medicine designates this live activity for a maximum of 18.25 Credits for the following professions: Physicians, Nurses/NPs, PAs, Pharmacists, Social Workers, and Counselors. See the website for more information about specific credit types.

See you in San Diego, CA from April 23 - 26, 2026!

Full poster information (including author information, poster PDFs, and more) is available on the conference website (https://annualconference.asam.org/) and in the ASAM Events app.

### POSTERS 1 - 68

Friday, April 25, 2025 | Aurora Pre-Function, Level 2 9:45 am – 10:30 am & 12:15 pm – 1:15 pm

- 1 Racial Disparities in Urine Toxicology Screening for Labor and Delivery Admissions Robert B. Levy, MD, FASAM; Mary Lonergan-Cullum, PhD; Cresta W. Jones, MD, FACOG, FASAM; Savannah Maynard Award Winner - Best Overall
  - **2** Race and Insurance Influence on Medications for Opioid Use Disorder *Emily A. Vachon; Suzanna Kitten, MD, DFAPA*
- **3 -** Leveraging Asian American & Pacific Islander Resilience in Substance Use Recovery Warren Yamashita, MD, MPH, FASAM; Connie Chen, MD; Jessica A.S. Wang, MD, MPH; Connie Tian Honorable Mention - Underserved
  - Population

    4 MOUD Treatment Receipt and
    Retention by Sociodemographics at a
  - Retention by Sociodemographics at a Safety-Net Health System
    Alexandra R. Tillman, MS; Emily Bacon, PhD
  - **5** Substance Treatment Phone Line Expansion Improves Connection to Treatment and Resources Andrea Bailey, CAS; Luke M. Still, MPH
  - **6 -** Scaling Up Low-Barrier Wound Care for People who Use Drugs Jessica K. Lin; Eleanor Turi, PhD, RN, CCRN
  - **7 -** Xylazine Positivity Rate Among Patients at an Urban Low-Barrier Access Clinic Joseph D'Orazio, MD, FAAEM, FACMT, FCPP, FASAM; Shruti Gujaran, MD
  - **8** Tianeptine "Gas Station Heroin" Products: Public Health Concern or Niche Substance Use? Kirsten E. Smith, MSW, PhD
  - **9 -** A Drug Identification Program as a Harm Reduction Initiative Shan Yin, MD, MPH, FAAP, FACMT
  - 10 Exploring Street Medicine's Acceptability: A Qualitative Study of Team Member Perspectives Ashleigh N. Herrera, PhD, LCSW; Presleigh Beshirs
- 11 Harm Reduction Vending
  Machines Increase Equitable Access
  to Naloxone and Health Supplies
  Ashleigh N. Herrera, PhD, LCSW
  Award Winner Associated
  Professional

- **12 -** Implementing an Opioid Overdose Prevention Program within a Community Mental Health Clinic Philip J. McFarland, MD
- 13 Implementation Determinants of Harm Reduction Integration in Outpatient Clinical Settings Emma A.R. Markus, MPH; Raagini Jawa, MD, MPH. FASAM
- **14** Physician Perspectives on Initiating Treatment of Hepatitis C during Hospitalization *Erin Bredenberg, MD, MPH*
- **15** Discharge on MOUD Reduces Relapse in Trauma Patients with Prior Opioid Dependence Hannah Bard; Robert E. Koegel, MS
- 16 Recovery Capital among Patients
  Receiving Buprenorphine Treatment for
  Opioid Use Disorder
  Christopher Rowe, PhD; Adam M. Bisaga, MD

  28 Quetiapine, A Novel Additive to
- **17** Attitudes of Patients Who Use Drugs Towards Policies Regarding In-Hospital Use Spencer Schell, MD
- **18** Barriers to Prescribing Varenicline and NRT in Inpatient Psychiatric Settings *Jude N. Nkwelle, MD; Anjali Pathak, MD*
- **19** Impact of Mental Health Conditions and Psychiatric Prescriptions on MOUD at Discharge Karen C. Guo; Kevin R. Wenzel, PhD
- **20 -** Emergency Department Utilization for OUD Before and After Receiving Buprenorphine from EMS *Jessica Heil, MPH; Rylie Jones*
- 21 Advancing the Evidence on Emergency Department and Hospital Linkage to Methadone Treatment Jasmine Barnes, MPH, CFRS; James Sherman, CRS, CHW; Maya Arora Award Winner - Representation in Research
  - **22 -** Secondary Outcomes from the START RCT to Improve OUD Care for Inpatients

    Kimberly Page, MS, PhD, MPH
  - **23 -** Needle-Free Lidocaine Administration Before XR-BUP Decreases Patient-Perceived Pain Score *Tirzah Wethern, MD, FASAM*

- 24 Prevalence of ADHD in Adults Seeking Methadone Treatment for Opioid Use Disorder Sophia Sugar, MD Honorable Mention – Resident
  - **25** Clinical Characteristic Differences Between Sexual Minorities and Heterosexuals with OUD Christopher L. Pfeltz , Jr.; Kevin R. Wenzel, PhD
  - **26 -** Factors Associated with Drug Harm Reduction Among Electronic Dance Music Event Attendees Eric Yang; Stella L. Chen; Katrina H. Ninh; Wayne Kuang, DO
- 27 Improving Methadone Access: Creating a Reliable Methadone Clinic Database in Los Angeles Darlene Lien; Caroline Sha; Kumar Felipe Vasudevan, MD Honorable Mention - Students
  - **28** Quetiapine, A Novel Additive to the Illicit Heroin Supply in Los Angeles Joseph R. Friedman, MD, PhD, MPH; Carla Marienfeld, MD, FASAM Award Winner – Resident
  - **29** Emergence of Local Anesthetics in the Los Angeles Illicit Fentanyl Supply *Caitlin A. Molina*; *Adam Koncsol, MPA*
  - **30 -** Coping with Crisis: Housing Instability, Food Insecurity, and Cannabis Use in Pregnancy Anyah Skipwith, MS
  - **31** Hepatitis C Virus Care Linkage for Peripartum Individuals with Opioid Use Disorder Elizabeth Charron, PhD; Marcela Smid, MD, MA, MS, FACOG
  - **32 -** Maternal Attachment Moderates Effects of Substance Use on White-Matter Microstructure Oakley R. Martin; Zu Wei Zhai, PhD
  - **33** Perinatal Quality Collaboratives: Enhancing Care for Pregnant and Postpartum Women with Substance Use Disorders and their Affected Newborns through Quality Improvement Allison S. Guarino, MPH
  - **34 -** A Longitudinal Analysis of PrEP Eligibility Among Women who Inject Drugs *Emily Hoff, MD*

### POSTERS 1 - 68

Friday, April 25, 2025 | Aurora Pre-Function, Level 2 9:45 am - 10:30 am & 12:15 pm - 1:15 pm

- **35** Breaking Barriers: Social Vulnerability and Retention among Pregnant Women with Opioid Use Vivian N. Kalu, MD
- **36** National Estimates of Alcohol Use Disorder Diagnosis and Treatment in Pregnancy, 2006-2019 Chloe Lessard, MPH, MJ; Jennifer Bello Kottenstette, MD, FASAM; Caitlin E. Martin, MD, MPH, FASAM
- **37 -** Impact of Integrated Substance Use and Obstetric Care on Delivery Outcomes Casey R. Tak, PhD, MPH
- **38** Treatment History among Patients with Recurrent Opioid Overdoses: A Multicenter Study Amanda Sutphin, BSHCA, EMT-P; Paul M. , Wax, MD, FACMT
- **39 -** Self-Harm as a Contributor to the "Fourth Wave:" Suicidality in Stimulant Overdoses

Stephanie T. Weiss, MD, PhD, FAACT, FASAM

**40 -** Family History Density: Impact on Participant Substance Use Onset and Duration

Carleigh Litteral; Michelle Martel, MS, PhD

- **41 -** Breaking the Cycle: Life-Saving ICD in Methadone-Induced Torsades de Pointes

  Haley Briggs, PA-C
- **742** Machine Learning to Assess Stimulant Therapy Risk for Stimulant Use Disorder Wen-Jan Tuan, DHA, MS, MPH Honorable Mention – Associated Professional
- **43** Innovative Interprofessional Education Model for Substance Use Disorder Care
  Carlos R. Dostal, MD, PhD
- **44 -** Opioid Use Disorder Medication Accessibility in Central and Outlying Texas Counties

  Carlos R. Dostal, MD, PhD
- **45** Age, Symptom Management, and Cannabis Use Disorder Risk: A Cross-Sectional Study Ian J. Starr; Amy Padia; Todd W. Fausnaught, MD, FAAFP, FASAM
- **46 -** Provider Experiences of SUD Management in Pediatric Hospitals: A Qualitative Study Adam Kronish, MD

- **47** Neuromodulation in Transitional Age Youth Substance Use Disorders: A Narrative Review *Kelly B. Ahern; Ismail Deniz, MD*
- **48** Perceived Need for Treatment Among Adults With Severe Substance Use Disorder

Samantha Brown, MPH

- **49** Reimagining SBIRT: Provider, Adolescent, and Caregiver Perceptions in Primary Care Kelly A. Johnson; Meredith Glass, MPH
- **50 –** Evaluating Adolescent Medicine Providers' Barriers to SUD Screening and Intervention *Emily Rider-Longmaid, MD, MBE* Honorable Mention – Fellow-in-Training
- 51 Elevating Patient Voices: Substance
  Use Care, Recovery Support, & Overdose
  Prevention
  Carmen Reid, MD; Patrick K. Ennis, MD, MPH,
  FAAFP, FASAM; Juleigh Nowinski Konchak,
  MD, MPH, FASAM; Sarah Elder, LCSW, CADC
  Award Winner Fellow-in-Training
  - **52** Barriers to Healthcare Utilization and Adolescent Prescription Drug Misuse During COVID-19 Nazifa Ibrahim; Samantha Rosenthal, PhD, MPH
  - **53** Pharmacy Barriers to Receiving Buprenorphine Addiction Treatment Through Telehealth Lauren Hendy, PhD; Marlene C. Lira, MPH
  - **54 -** Determinants of Increased Travel Burden for Patients Treated with Buprenorphine

Sahar Yazdanfard, MS, PhDC Award Winner - Student

- **55 -** Who Gets Treatment? Substance Use Disorder Treatment Enrollment after Traumatic Injury Kaylee McCord; Anne K. Buck, MS
- **56** Bromazolam Withdrawal Requiring ICU Admission: Case Report of Designer Benzodiazepine Use Benjamin Dralle, MD
- **57 -** Impact of Gabapentin Regulation on Opioid Overdose Trends, 2013-2022 Conrad Say; Hiroko Furo, MD, PhD, FASAM
- **58 -** Assessing Readability and Stigma of ChatGPT's Opioid Use Disorder FAQs Daniel Heringer, MD

- **59** Protracted Benzodiazepine Withdrawal in a Psychiatric Patient with Polysubstance Use Morgan E. Zipperly, MD, PhD
- **60 -** Low-Dose Dexmedetomidine: Repurposing an Intravenous Agent for Opioid & Alpha 2 Withdrawal Phil Durney, MD; Meg Carter, MD; Kory London, MD
- **61** Opioid Withdrawal and Autonomic Complications Associated with Medetomidine Adulteration Kory London, MD; Samantha Huo, MD, MPH, MS, FASAM; Philip Durney, MD; Jeanmarie Perrone, MD, FASAM
- **62** Buprenorphine for Naltrexone-XR-Precipitated Opioid Withdrawal Samantha Huo, MD, MPH, MS, FASAM; Jessica Moore, MD, FAAEM, FASAM
- **63** Addressing Gaps in Buprenorphine Treatment Among Black and Non-English-Speaking Patients
  Sarah E. Wakeman, MD, FASAM; Lucille Jordan, LICSW
- **64** Polymicrobial Bacteremia from Licking Syringe Plungers: A Case Report and Scoping Review Molly M. Perri, MD; Cara Borelli, DO; Alyssa Cheng, DO; Amy Bopp, APRN
- **65** Kratom and Kava Use Disorder & Withdrawal Management: A Case Study Cynthia Pathmathasan, MD, MA
- **66** Recognizing Nitrous Oxide Toxicity: Key Neuropsychiatric Symptoms and Diagnostic Clues Theodore Tsonis, MD
- **67 -** Sustained Positive Buprenorphine after LAIs and Naltrexone Micro-Dosing in Treating OUD

  Anyun Ma, MD
- **68** Improving Lives, Saving Money: Housing Solutions for Substance Use Disorders

Justin Grant, LCSW, MPH; Jeané Tyler, LCSW, LPC, CCP, QMAP; Clare McGinley; Matthew Bustos, CAS

### POSTERS 71 - 137 |

Saturday, April 26, 2025 | Aurora Pre-Function, Level 2 9:45 am - 10:30 am & 12:15 pm - 1:15 pm

- 71 Race, Ethnicity, & Language Differences in Medications for Alcohol Use Disorder Prescribing Daniel Liauw, MD, MPH
- 72 Racial Differences in LGBTO+ Substance Use: Insights from All of Us

Michelle R. Dalton, PhD, LPC; Divya Patel; Maria Nash; Rachel Livingston, MA

- 73 Racial Disparities in Mental Health and Substance Use during the COVID-19 Pandemic Yen-Han Lee, MPH, PhD
- **74 -** An OUD Support Line Improves Opioid Use Disorder Treatment in Hospitalized Patients Kevin Chung, MD
- **75** Optimizing Telephone Call Reminders to Improve Appointment Attendance at Outpatient Clinic Bridget Oppong-Darko, DNP, FNP-C, RN
- 76 Facilitators to Patients with Substance Use Disorders Seeking Care in the ED Timothy S. Kelly, MD
- 77 Patient Factors Associated with Hospital Discharge on Buprenorphine Versus Methadone Alexis N. Coffee, PharmD
- **78** Methadone Dose and Patient-Directed Discharge in Persons with Prior Methadone Enrollment William M. Garneau, MD, MPH, MHS; Rebecca 791 – High Risk and Underserved: Meredith, MD; Rosalyn Stewart, MD, MS, MBA Honorable Mention - Best Overall
  - **79** Inpatient OUD Management: Associations with PDD, Readmission, and Mortality Sijie J. Wang, MD; Calvin Bohner
  - 80 Comparative Outcomes of Opioid Withdrawal Management for Patients Admitted with Bacteremia Samuel Handy; Timothy Garton; Vikranth Induru, MD
  - 81 Deep Learning-Based Detection of Xylazine Exposure from Wound Imaging Pranav Sompalle; Abeed Sarker, PhD, FAMIA Honorable Mention - Student
    - 82 Augmented Reality Technology **Engages Opioid Use Disorder Patients** in Their Treatment Melodie K. Isgro, MD, FASAM

- **83** Drug Supply Monitoring: Feedback from People Who Use Drugs Amy J. Arthur; Alexandra Collins, PhD Honorable Mention - Student
  - 84 Meta-Analysis of the Therapeutic Role of TMS and tDCS in Opioid Disorder Victoria Gomes Andreata, MD; Akhil Anand, MD. FASAM
  - 85 Alcohol Use Disorder Medication Initiation During Alcohol Withdrawal Hospitalizations Eden Y. Bernstein, MD, MPH
  - 86 Enhancing Viral Hepatitis Harm Reduction through a Comprehensive Addiction Consult Service TaReva Warrick-Stone, DO
  - 87 Sex, Socioeconomic Status, and Self-Perceived Risk of Opioid Overdose Daniela Wong Pacheco; Rebecca L. Hill, DrPH
  - 88 Prevalence and Correlates of AUD Diagnoses among Users of HIV Pre-Exposure Prophylaxis Rishit Yokananth; Anton Avanceña, PhD
  - 89 Risk Factors of Severe Maternal Morbidity in Individuals with Methamphetamine Use Rachel Mnuk, MD, MPH
  - 90 Variation in Toxicology Testing for Substance Exposure in Pregnancy in Michigan Hospitals Lauren Oshman, MD, MPH, FAAFP
  - Drug and Sexual Patterns Among Women Who Inject Belén Hervera, MPH Honorable Mention - Representation in Research
- **92** Intimate Partner Violence Support in Perinatal Substance Use: Patient and Provider Insights Tien C. Nguyen; Elizabeth E. Krans, MD, MSc Award Winner - Underserved **Population** 
  - 93 Perceptions of Fertility among Treatment-Seeking Women with Opioid Use Disorder Jennifer Bello Kottenstette, MD, FASAM
  - 94 Vascular Changes in the Placentas of Buprenorphine Exposed Pregnancies Chloe Lessard, MPH, MJ

- 95 Perinatal Opioid Use Disorder Program in the Heart of the Opioid Epidemic
- Maggie E. McGinty, MPH; Davi da Silva; Nia M. Bhadra-Heintz, MD, MS, FASAM
- 96 Perspectives of Pregnant and Postpartum Persons on Xylazine **Education and Home Testing** Ilana Hull, MD, FASAM; Raagini Jawa, MD, MPH, FASAM; Ellen Stewart; Samantha Mayo
- 97 Timeouts May Reduce Unnecessary Child Welfare Reports for Substance Exposed Newborns Tomiyuri Lewis; Gabriel Salazar; Angela E. Kim, MPhil; Daniel Zhang; Dominika Seidman, MD, MAS
- 98 Breaking Barriers: Advancing Addiction Care for Young Immigrant Adults

Jasmine Alagoz

- 99 The Kids are Not Alright: Missed Opportunities for Inpatient Adolescent Nicotine Screening Anna Carleen, MD
- **100 -** Trends in United States Adolescent and Young Adult Overdose Fatalities, 1999-2023 Yinan Chen; Zhu Wang, PhD
- 101 Marijuana Exposures and Poisonings of Children Aged 12 and Under

Raymond Bertino, MD

- 102 Adolescent-Specific Risk and Protective Factors of Substance Use Among High School Students Richard C. Wang; Daniel Lipin, PhD
- **103 -** Adolescent and Caregiver Perspective on Substance Use Screening in the Emergency Department

Stephen M. Sandelich, MD

- 104 Medication-Assisted Recovery Anonymous vs 12-Step Groups: Comparing MOUD Stigma Experiences Rachel K. Totaram, MHA
- **105 -** Characteristics Associated with Overdose after Opioid Prescription to Younger Individuals Scott G. Weiner, MD, MPH, FASAM

### POSTERS 71 - 137

Saturday, April 26, 2025 | Aurora Pre-Function, Level 2 9:45 am - 10:30 am & 12:15 pm - 1:15 pm

106 - Naloxone and Medication for Opioid Use Disorder in US Emergency Departments

Scott G. Weiner, MD, MPH, FASAM

**107 -** Perioperative Buprenorphine Use Protects Against Long-Term Opioid Use

Shruthi Prabhakar; Margaret R. Rukstalis, MD

- 108 Instruments Assessing Long-Term Opioid Therapy for Chronic Pain: A Scoping Review Alyssa Cheng, DO
- 109 Implementing Revised Methadone Treatment Regulations at **NYS Opioid Treatment Programs** Pamela Mund, MD, FASAM
- 110 Expanding Community-Led Partnerships: Residency Integration in a Harm Reduction Clinic David S. Edelman, MD, MPH
- **111 -** People Can Recover: Qualitative Findings from a Statewide Naloxone Distribution Project Kathleen Monahan, MPH
- 112 Retrospective Analysis of Buprenorphine Initiation in an Urban Street Medicine Program Jasmine King, MA; Elizabeth A. Abrams, **MSPH**
- 113 Rock Bottom Is Not a Motivator: From Opioid Addiction to Human Flourishing Shiv Ayappa; Michael Fingerhood, MD, FACP, DFASAM
- **114** Stigmatizing Language in the Medical Record After Addiction Consult Service Implementation Ryder Cuppett; Kristin Daniel, PharmD, BCPS, DPLA
- 115 Substance Use Disorder Patient Experience with "Leave Behind Naloxone" in the Community Winney Zhao, MPH; Rylie Jones
- 116 Word of Mouth: The Key to Community Connections and HR Among PWUD Kelsey Leon, MSc; Elizabeth H. Nguyen; Haydr Dutta
- 117 Treating Opioid Use Disorder: Perspective of FQHC Clinicians in Los **Angeles**

Andrew Schmidt, ME; Kurtis Pruitt

- 118 The UCSF SBIRT Collaborative Care Program for SUD: Design, Development, and Implementation Jason M. Satterfield, PhD
- **119 -** Evaluation of a Family Medicine Contingency Management Program for Substance Use Disorder James LaRosa, MD
- 120 Advancing Alcohol Use Disorder Treatment Through Clinician Training Program

Melissa B. Weimer, DO, MCR, DFASAM

- **121 Predictors of Retention During** and After Residential Treatment for Substance Use Disorders Ninad Athale, MD, FASAM
- **122 -** Prevalent Comorbidities Associated with Substance Use Disorder in East Texas (2021-2024) Liz Penaloza Villalobos, MD; Tuan D. Le, MD. MPH. DrPH
- **123 -** Heart Transplant Outcomes in Substance Use Disorder: A Nationwide Cohort Study Samuel Cvr. PhD
- **124 -** Psychogenic Non-Epileptic Seizures (PNES) in a Case of Alcohol Withdrawal Syndrome Edward W. Hernandez, MD; Nikita Gettu, DO
- 125 Yikes! Methadone to **Buprenorphine Transition During** Pregnancy, in Jail, via Telephone Carolyn Wong, MD; Alison C. Lynch, MD, MS
- **126 -** Buprenorphine Rescue for XR Naltrexone-Precipitated Opioid Withdrawal: A Case Report Hannah Kissel-Smith, MD; Megan Lemay, MD
- 127 Initiating Extended-Release Injectable Buprenorphine in Primary Care without a Test Dose Linda Wang, MD, FASAM

- 128 No, No Nootropics! A Case of Tianeptine and Phenibut Withdrawal/ Use Disorder Kevin Wang, MD
- 129 Rapid Outpatient Initiation of Long-Acting Injectable Buprenorphine: A Case Series

Elliott Brady, MD, MPH; Clarissa O'Conor, MD: Andrea U. Jakubowski, MD, MS

- 130 Importance of Collaborative Care for Adolescents with OUD: A Case Report Emily Tixier, MD
- **131 -** Self-Directed Ketamine Therapy and Withdrawal Syndrome: A Case Report

Zachary J. Brown, DO

132 - Breaking the Cycle: GLP-1/GIP Agonist Treatment and Alcohol Use Disorder

Yasimin Taheri, MD

- 133 Disulfiram: An Effective Yet Underutilized Drug for AUD Jasmin Shores, MD, MPH
- 134 Long-Acting Injectable Buprenorphine: A Vein-Saving Victory in Pediatric Case Anneke Bulthuis, DO; Bobby Lindquist, DO
- **135** Not Just Fentanyl: Protracted Withdrawal from Para-Fluorofentanyl Mohammad Hassan, MD; Nicole Muller, MD; Zainab Alam, MS
- 136 A Case of Tianeptine Overdose Requiring ICU Admission John Buyske, MD
- 137 Years of Life Lost from Stimulant-Involved Cardiovascular Mortality, 2014-2023 Rebecca A. Harris, MD, MSc, FASAM







### Awards

### **Annual Award Recipients**



**Gitlow Leadership Award** William F. Haning, III, MD, DLFAPA, **DFASAM** 



Diversity, Equality, Inclusion, and **Justice Award** Ruchi M. Fitzgerald, MD, FAAFP, DFASAM

All awards presented at the ASAM Annual Awards

& Updates session on Saturday, April 26 at 2:45 pm to 4:00 pm in the Colorado Ballroom, Level 3!



John P. McGovern Award Yngvild K. Olsen, MD, MPH, **DFASAM** 



**Public Policy Award** Vania P. Rudolf, MD, MPH, DFASAM



R. Brinkley Smithers **Distinguished Scientist Award** Edward V. Nunes, Jr., MD, FASAM



**Fellowship Directors Award** Timothy K. Brennan, MD, MPH



**Annual Award** Cara A. Poland. MD. MEd. FACP. **DFASAM** 



Media Award Maia Szalavitz

### **Diversity Travel Scholarship Recipients**

Mohit Chhatpar, MD Evonemo Esievoadje, MD, MBBS, CCFP Sara Gabere, MD Sand Mastrangelo, MD **Ahmed Nahian** Henrique Oliva, MD, PhD Amanda Perez, MD Thanh Phan, MD Adriana Rush Uyonne Ugwuoke, MD

### **Ruth Fox Scholarship Recipients**

Ngozi Adaralegbe, MD, PhD Jayabhargav Annam, MD Oluchi Anuniru, MD Fauzia Arain, MD Daniel Arriola, MD Lem Atanga McCormick, MD, Sangeeta Iyer, MD, MPH **MPH** Roshni Bhat, MD Joshua Bia, MD Kyle Bivins, MD, MS Robert Bockstruck, MD Elliott Brady, MD Endy Cadet, MD Raymond Chung, MD John Robyn Diez, MD

Mary Geist, MD Jared Harp, MD Emily Hoff, MD Alison Holt, MD Brian Kaszuba, MD Karampreet Kaur, MD Adam Kronish, MD Margot Mellette, MD Mary Ashley Mercer, MD Zain Nayani, DO, MPH Veronica Pace, MD Cynthia Pathmathasan, MD Cristina Perez Caro, MD

Joseph Friedman, MD

Molly Perri, MD Tyler Reese, MD Brandon Salzman, DO Shima Shakory, MD, CCFP, MPH Benjamin Shuham, MD Hannah Stone, MD Aishwarya Thakur, MD Queeneth Uwandu, MD Namrata Walia, MD, MPH, MHA Corey Walsh, MD Paula Whitmire, MD

### Awards

### **Abstract Award Recipients**



**Abstract Award: Best Overall** Robert B. Levy, MD, FASAM



**Abstract Award: Resident**Joseph Friedman, MD, PhD, MPH



**Abstract Award: Associated Professional** Ashleigh Herrera, PhD, LCSW



**Abstract Award: Student** Sahar Yazdanfard, MS, PhDc



**Abstract Award: Fellow-in-Training** Carmen Reid, MD



Abstract Award: Underserved Population
Tien Nguyen



Abstract Award: Representation in Research
Jasmine Barnes, MPH, CFRS

### 2025 Distinguished Fellows

Saurabh B. Bhardwaj, MD, FAPA, DFASAM Chad Elkin, MD, FAACP, DFASAM Amy de la Garza, MD, DFASAM Nzinga Harrison, MD, DFASAM Jeanne Kapenga, MD, DFASAM Tipu Khan, MD, DFASAM Jason D. Kirby, DO, MBA, DFASAM James Latronica, DO, DFASAM Lewei (Allison) Lin, MD, MS, DFASAM Clifton F. Lord, MD, DFASAM Katrina Nickels, MD, DFASAM Robert C. Sherrick, MD, DFASAM Pamela J. Shultz, MD, DFASAM James E. Sturmi, III, MD, DFASAM Arturo C. Taca, Jr., MD, DFASAM Jan Widerman, DO, FACOP, FAAP, DFASAM

Kenneth Zoucha, MD, DFASAM

#### **Abstract Award Honorable Mentions**

Honorable Mention: Best Overall William M. Garneau, MD, MPH, MHS

**Honorable Mention: Associated Professional** 

Wen-Jan Tuan, DHA, MS, MPH

Honorable Mention: Fellow-in-Training

Emily Rider-Longmaid, MD, MBE

Honorable Mention: Representation in Research

Belén Hervera, MPH

Honorable Mention: Resident

Sophia Sugar, MD

**Honorable Mention: Student** 

Amy J. Arthur Darlene Lien Pranav Sompalle

**Honorable Mention: Underserved Population** 

Warren Yamashita, MD, MPH, FASAM



Thank you to everyone who donated to our 2024 Give Hope Now Initiative. Your support makes a meaningful difference, helping us bring hope and positive change to individuals and families affected by addiction. Together, we are transforming lives, breaking the cycle of addiction, and creating a brighter, healthier future. We couldn't do it without you!

### TOP INDIVIDUAL DONORS

Anthony Albanese, MD, DFASAM
Lawrence S. Brown, Jr., MD, MPH, FACP, DFASAM
Sonya Chang
David Kuo, MBA & Julia Chang, MS, MBA
Kenneth I. Freedman, MD, MS, MBA, FACP, AGAF, DFASAM
Stuart Gitlow, MD, MPH, MBA, DFAPA, DFASAM
William F. Haning, III, MD, DLFAPA, DFASAM
Margaret A. E. Jarvis, MD, DFASAM
Michael M. Miller, MD, DFASAM, DLFAPA
Alvin D. Pelt, MD, FASAM
Edwin A. Salsitz, MD, DFASAM
Timothy Wiegand, MD, FACMT, FAACT, DFASAM

Top Donors represent those individuals that gave \$5,000 or more to the Give Hope Now Initiative.

### Act of Care for ASAM

We invite you to support causes that are close to your heart. With our partner, Free Will, you can create a will and:

- Protect who and what matters most to you
- Gain long-term peace of mind
- Elevate your act of care by supporting the causes you love

### Visit FreeWill.com/asam to get started on your will today!

If you have already included a gift to ASAM in your will, please fill out the brief form at FreeWill.com/Record/asam so we can thank you for your generosity.

Questions? Reach out at Rebecca Yannopoulos, CFRE ryannopoulos@asam.org or 301.392.2401

# eLearning Center & Claiming Credit

#### **CLAIMING CREDIT:**

Claim credit anytime between April 28, 2025 and April 28, 2026.

#### **Annual Conference and Pre-Conference Course Registrants:**

- 1. Go to https://eLearning.ASAM.org in your web browser.
- 2. **Log in** using your ASAM.org username and password (the same credentials used for conference/pre-conference registration).
- 3. Access your dashboard:
  - a. On a computer: Click "My Dashboard" in the top menu.
  - b. On a mobile device: Tap the three horizontal lines in the header, then select "Dashboard."
- 4. Find your course: Under "Courses and Sessions," select "Evaluation & Certificate - Live Attendees of [Annual Conference or Pre-Conference Coursesl."
- 5. **Complete the evaluation:** Click "Complete Evaluation" and then "Fill out Survey."
- 6. Claim your credits: Click "Claim Credit & Certificate," then "Claim Medical Credits.""
- 7. **Enter details:** Choose your provider type, enter the hours attended, and click "Submit."
- 8. Save your certificate: Print or download it for your records.



### WATCH SESSIONS ON-DEMAND:

Available May 26, 2025 to May 26, 2028.

Relive the conference or catch sessions 56th Annual Conference and Prewhen they become available.

### Looking for more session information?

The full conference schedule, including updates, onsite changes, speaker information, presentation slides, and more, is available on the conference website http://annualconference.asam.org and in the ASAM Events app.



1. Download "ASAM Events" in the App Store or Google Play



2. Click on "ASAM Annual 2025"

3. Create a new account



- Everyone will need to create a new account the first time they open the ASAM Annual 2025 event within the app. The new account does not need to have the same email addresss used during registration.
- If you want to log in to your account on multiple devices, use the password that was emailed to you after you created your account.



# save the Date

ASAM VIRTUAL

REVIEW COURSE
in Addiction Medicine

July 23 – 24, 2025 | Live Virtual Course reviewcourse.asam.org
(Registration Open)



September 15 – 16, 2025 | Washington, DC ASAM.org/Advocacy/AMAC (Registration Open)



April 23 – 26, 2026 | San Diego, CA annualconference.asam.org (Registration Opens October 2025)

Ø online learning

Visit elearning.asam.org to explore ASAM's complete library of courses and content!

### Don't miss a single booth or activity!

Familiarize yourself with the schedule and floor plan with our Sponsor & Exhibitor Guide. This serves as the ultimate roadmap to help you navigate the Exhibit Hall and make the most of your visit, as well as recognize the supporters who helped make this event happen!





American Society of Addiction Medicine 11400 Rockville Pike, Suite 200 Rockville, MD 20852 www.ASAM.org